OncoSpherix
- Biotech or pharma, therapeutic R&D
OncoSpherix is a preclinical-stage cancer drug development company striving to improve quality of life and survival of patients with many forms of advanced cancers. The initial focus is on first-in-class small molecule inhibitors that target the hypoxia-inducible factor 1 (HIF-1) pathway, thereby disrupting essential processes that fuel tumor growth, metastasis, and resistance to therapy. Preclinical efficacy has been shown with multiple types of cancer, including lung, breast, pancreas, eye melanoma, and brain. OncoSpherix’s lead family of HIF-1 inhibitors reduces primary tumor growth by 60-85 % in multiple mouse models of cancer, including, uveal melanoma, lung, breast, and pancreatic cancers. Metastases are reduced or fully blocked in all cancers tested. HIF-1 is not needed in well-oxygenated normal tissues, so the consequence of its inhibition is primarily experienced in tumors. A strong therapeutic synergy occurs when combining OncoSpherix’s HIF-1 inhibitor with some therapies.
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}